

PACEF Lincolnshire Primary Care – Quick Guide to selecting inhalers for COPD patients



	Low Inspiratory Flow <30 L/min		High Inspiratory Flow >30 L/min		
	pMDI and spacer is the device of choice for patients who have low inspiratory <u>time</u>		First line choice	Second line choice	Third line choice
	First line choice	Second line choice	First line choice	Second line choice	Third line choice
SABA	Salbutamol pMDI +/- spacer	Salamol Easi-Breathe	Salbutamol Easyhaler		
SAMA	Ipratropium pMDI +/- spacer				
LABA	Atimos pMDI (Formoterol) +/- spacer	Salmeterol pMDI +/- spacer	Formoterol Easyhaler	Serevent Accuhaler (Salmeterol)	
LAMA (LAMA inhalers can cause a dry mouth)	Spiriva Respimat (Tiotropium)		Braltus Zonda (Tiotropium)	Seebri Breezehaler (Glycopyrronium) Elklira Genuair (Aclidinum) Spiriva Handihaler (Tiotropium)	Incruse Ellipta (Umeclidinum)
LABA/LAMA	Spiolto Respimat (Tiotropium/ Oldactero)		Ultibro Breezehaler (Indacaterol/ Glycopyrronium)	Duaklir Genuair (Aclidinum/Formoterol)	Anoro Ellipta (Vilanterol/ Umeclidinum)
ICS/LABA (ICS inhalers can cause oral thrush – instruct to rinse out mouth after use)	Fostair pMDI (Budesonide/ Formoterol) +/- spacer		Duosp Spiromax (Budesonide/ formoterol) Symbicort Turbohaler (Budesonide/ formoterol)	Fostair NEXThaler (Beclomethasone/ formoterol)	Relvar Ellipta (Vilanterol/Fluticasone Furoate*) Seretide Accuhaler (Fluticasone Propionate*/ Salmeterol) Airflusal Forspiro (Fluticasone Propionate*/Salmeterol)
LABA/LAMA/ ICS	Trimbow pMDI (Beclomethasone/formoterol/ glycopyrronium) +/- spacer		Trimbow pMDI (Beclomethasone/formoterol/ glycopyrronium) + spacer		Trelegy Ellipta (Fluticasone propionate*/ Vilanterol/Umeclidinum) Only to be used if Trimbow pMDI ± spacer is unsuitable for the patient

*Caution higher potency steroid. Using FF has a higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia - has been confirmed in ICS studies using FF even at low doses (GOLD 2019).

Other inhaler devices approved for COPD are detailed on the Lincolnshire formulary website available via: <http://www.lincolnshirejointformulary.nhs.uk/>

For **asthma/COPD overlap syndrome** follow the asthma pathway

For advice on when to initiate treatment please refer to the following stepwise approach: <https://www.nice.org.uk/guidance/ng115/resources/visual-summary-treatment-algorithm-pdf-6604261741>

Ratified July 2019. Due for review July 2021